Goldman Sachs Group Inc Halozyme Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,974,634 shares of HALO stock, worth $92.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,974,634

Previous 778,891 153.52%

Holding current value

$92.7 Million

Previous $40.8 Million 177.0%

% of portfolio

0.02%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $61.3 Million - $77 Million	1,195,743 Added 153.52%	1,974,634 $113 Million
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $1.61 Million - $2.23 Million	-42,495 Reduced 5.17%	778,891 $40.8 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $24.3 Million - $30.2 Million	-720,224 Reduced 46.72%	821,386 $33.4 Million
Q4 2023 Feb 13, 2024	SELL	$33.32 - $42.1 $6.36 Million - $8.03 Million	-190,795 Reduced 11.01%	1,541,610 $57 Million
Q3 2023 May 14, 2024	BUY	$36.46 - $44.03 $6.96 Million - $8.4 Million	190,795 Added 12.38%	1,732,405 $66.2 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $6.08 Million - $7.34 Million	166,649 Added 10.64%	1,732,405 $66.2 Million
Q2 2023 May 14, 2024	SELL	$30.28 - $38.74 $1.26 Million - $1.61 Million	-41,542 Reduced 2.58%	1,565,756 $56.5 Million
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $1.26 Million - $1.61 Million	-41,542 Reduced 2.58%	1,565,756 $56.5 Million
Q1 2023 May 14, 2024	SELL	$32.86 - $55.7 $12.7 Million - $21.5 Million	-385,908 Reduced 19.36%	1,607,298 $61.4 Million
Q1 2023 May 11, 2023	SELL	$32.86 - $55.7 $12.7 Million - $21.5 Million	-385,908 Reduced 19.36%	1,607,298 $61.4 Million
Q4 2022 May 14, 2024	BUY	$40.06 - $59.44 $371,155 - $550,711	9,265 Added 0.47%	1,993,206 $113 Million
Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $371,155 - $550,711	9,265 Added 0.47%	1,993,206 $113 Million
Q3 2022 May 14, 2024	BUY	$38.53 - $51.78 $12.4 Million - $16.7 Million	322,702 Added 19.43%	1,983,941 $78.4 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $12.4 Million - $16.7 Million	322,702 Added 19.43%	1,983,941 $78.4 Million
Q2 2022 May 14, 2024	BUY	$37.35 - $48.3 $4.47 Million - $5.78 Million	119,629 Added 7.76%	1,661,239 $73.1 Million
Q2 2022 Aug 15, 2022	SELL	$37.35 - $48.3 $11.3 Million - $14.6 Million	-301,458 Reduced 15.36%	1,661,239 $73.1 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $25.7 Million - $33 Million	-802,550 Reduced 29.02%	1,962,697 $78.3 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $15.8 Million - $20.3 Million	497,705 Added 21.95%	2,765,247 $111 Million
Q3 2021 Nov 10, 2021	BUY	$38.47 - $46.42 $87.2 Million - $105 Million	2,267,542 New	2,267,542 $92.2 Million

Others Institutions Holding HALO

# of Institutions

543

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.54B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Halozyme Therapeutics, Inc. Transaction History